Companies / Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc.

Nasdaq: INTSCIK 1567264SHELTON, CT

Financials

Revenue—
Net income$-11.61M
Total debt—
Cash$9.53M
Diluted EPS$-8.56
Shares outstanding3.3M

Ownership

3.3M shares outstanding · as of Aug 7, 2026
7.1%Insiders
Ownership
Insiders7.12%232,564
Institutions1.56%51,019
Public float91.31%2,981,296

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 3

View all →
Insider% of sharesShares
Bender Lewis HCEOPresident and CEO · Director
3.63%118,549
Wesolowski John MPrincipal Accounting Officer
2.61%85,354
Talamo JosephChief Financial Officer
0.88%28,661

Institutional holders 2

View all →
HolderValue% of shares
Geode Capital Management, LLC$153.0K0.80%
Nano Cap New Millennium Growth Fund L P$147.0K0.77%

Activity

Mar 31, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q1 2026
as of
Geode Capital Management, LLC
13F manager
NewCommon Stock$153.0K+26K
26,019
0.80% of shares
low
Q1 2026
as of
Nano Cap New Millennium Growth Fund L P
13F manager
NewCommon Stock$147.0K+25K
25,000
0.77% of shares
low

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
INTSCommon StockEquity45828J202BBG00B57FZV6